May 28, 2026
GSK's Experimental Hepatitis B Drug Achieves Functional Cure in Nearly 1 in 5 Patients in Late-Stage Trials
GSK reported that its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, vastly outpacing current treatments and raising hopes for a finite treatment course as an alternative to lifelong therapy.
2 sources
00